Metabolomics and Metabolic Reprogramming in Kidney Cancer

被引:76
|
作者
Weiss, Robert H. [1 ,2 ]
机构
[1] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA
[2] VA Northern Calif Hlth Care Syst, Med Serv, Sacramento, CA USA
基金
美国国家卫生研究院;
关键词
Kidney cancer; metabolomics; therapeutics; reprogramming; RENAL-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; TUMOR-SUPPRESSOR LKB1; P53-INDUCIBLE REGULATOR; REDUCTIVE CARBOXYLATION; GLUTAMINE-METABOLISM; ARGININE DEPRIVATION; GROWTH; INHIBITOR; AKT;
D O I
10.1016/j.semnephrol.2018.01.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney cancer, or renal cell carcinoma (RCC), is a disease of increasing incidence that commonly is seen in the general practice of nephrology. Despite this state of affairs, this fascinating and highly morbid disease frequently is under-represented, or even absent, from the curriculum of nephrologists in training and generally is underemphasized in national nephrology meetings, both scientific as well as clinical. Although classic concepts in cancer research in general had led to the concept that cancer is a disease resulting from mutations in the control of growth-regulating pathways, reinforced by the discovery of oncogenes, more contemporary research, particularly in kidney cancer, has uncovered changes in metabolic pathways mediated by those same genes that control tumor energetics and biosynthesis. This adaptation of classic biochemical pathways to the tumors advantage has been labeled metabolic reprogramming. For example, in the case of kidney cancer there exists a near-universal presence of von Hippel-Lindau tumor suppressor (pVHL) inactivation in the most common form, clear cell RCC (ccRCC), leading to activation of hypoxia-relevant and other metabolic pathways. Studies of this and other pathways in clear cell RCC (ccRCC) have been particularly revealing, leading to the concept that ccRCC can itself be considered a metabolic disease. For this reason, the relatively new method of metabolomics has become a useful technique in the study of ccRCC to tease out those pathways that have been reprogrammed by the tumor to its maximum survival advantage. Furthermore, identification of the nodes of such pathways can lead to novel areas for drug intervention in a disease for which such targets are seriously lacking. Further research and dissemination of these concepts, likely using omics techniques, will lead to clinical trials of therapeutics specifically targeted to tumor metabolism, rather than those generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective than existing drugs and to have far fewer adverse effects. This review provides a general overview of the technique of metabolomics and then discusses how it and other omics techniques have been used to further our understanding of the basic biology of kidney cancer as well as to identify new therapeutic approaches. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [21] Metabolic reprogramming in cancer and senescence
    Zhang, Yuzhu
    Tang, Jiaxi
    Jiang, Can
    Yi, Hanxi
    Guang, Shu
    Yin, Gang
    Wang, Maonan
    MEDCOMM, 2025, 6 (03):
  • [22] Metabolic Reprogramming and Vulnerabilities in Cancer
    Lyssiotis, Costas A.
    Nagrath, Deepak
    CANCERS, 2020, 12 (01)
  • [23] Mitochondrial metabolic reprogramming in diabetic kidney disease
    Fan, Xiaoting
    Yang, Meilin
    Lang, Yating
    Lu, Shangwei
    Kong, Zhijuan
    Gao, Ying
    Shen, Ning
    Zhang, Dongdong
    Lv, Zhimei
    CELL DEATH & DISEASE, 2024, 15 (06):
  • [24] Reprogramming of Metabolism in Kidney Cancer
    Wettersten, Hiromi, I
    SEMINARS IN NEPHROLOGY, 2020, 40 (01) : 2 - 13
  • [25] Metabolic reprogramming heterogeneity in chronic kidney disease
    Miguel, Veronica
    Kramann, Rafael
    FEBS OPEN BIO, 2023, 13 (07): : 1154 - 1163
  • [26] Targeting Metabolic Reprogramming in Polycystic Kidney Disease
    Boletta, Alessandra
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (12): : 1768 - 1770
  • [27] Characterization of metabolic reprogramming by metabolomics in the oncocytic thyroid cancer cell line XTC.UC1
    Kurashige, Tomomi
    Shimamura, Mika
    Hamada, Koichiro
    Matsuse, Michiko
    Mitsutake, Norisato
    Nagayama, Yuji
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [28] Characterization of metabolic reprogramming by metabolomics in the oncocytic thyroid cancer cell line XTC.UC1
    Tomomi Kurashige
    Mika Shimamura
    Koichiro Hamada
    Michiko Matsuse
    Norisato Mitsutake
    Yuji Nagayama
    Scientific Reports, 13
  • [29] Untargeted and spatial-resolved metabolomics characterize serum and tissue-specific metabolic reprogramming in acute kidney injury
    Xu, Bei
    Li, Wanyi
    Zhang, Yamei
    Chen, Yan
    Feng, Jiafu
    Song, Xiangrong
    HELIYON, 2023, 9 (11)
  • [30] Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα
    Yan, Min
    Qi, Huan
    Xia, Tian
    Zhao, Xinjie
    Wang, Wen
    Wang, Zhichao
    Lu, Chang
    Ning, Zhen
    Chen, Huan
    Li, Tongming
    Tekcham, Dinesh Singh
    Liu, Xiumei
    Liu, Jing
    Chen, Di
    Liu, Xiaolong
    Xu, Guowang
    Piao, Hai-long
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 91 : 18 - 29